These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23444281)

  • 1. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.
    Stringer F; Ploeger BA; DeJongh J; Scott G; Urquhart R; Karim A; Danhof M
    J Clin Pharmacol; 2013 Mar; 53(3):256-63. PubMed ID: 23444281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
    Stringer F; DeJongh J; Scott G; Danhof M
    J Clin Pharmacol; 2014 Apr; 54(4):453-61. PubMed ID: 24214217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
    Stringer F; Scott G; Valbuena M; Kinley J; Nishihara M; Urquhart R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):423-30. PubMed ID: 22960998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.
    Nishihara M; Hiura Y; Kawaguchi N; Takahashi J; Asahi S
    Drug Metab Pharmacokinet; 2013; 28(6):475-84. PubMed ID: 23648677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.
    Chung JY; Cho JY; Yu KS; Kim JR; Jung HR; Lim KS; Jang IJ; Shin SG
    Clin Pharmacol Ther; 2005 Jun; 77(6):486-94. PubMed ID: 15961980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
    He X; Hesse LM; Hazarika S; Masse G; Harmatz JS; Greenblatt DJ; Court MH
    Br J Clin Pharmacol; 2009 Nov; 68(5):721-30. PubMed ID: 19916996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer.
    Park J; Chen L; Shade K; Lazarus P; Seigne J; Patterson S; Helal M; Pow-Sang J
    J Urol; 2004 Jun; 171(6 Pt 1):2484-8. PubMed ID: 15126881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.
    Nishihara M; Sudo M; Kawaguchi N; Takahashi J; Kiyota Y; Kondo T; Asahi S
    Drug Metab Dispos; 2012 Feb; 40(2):249-58. PubMed ID: 22028317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables.
    Navarro SL; Chen Y; Li L; Li SS; Chang JL; Schwarz Y; King IB; Potter JD; Bigler J; Lampe JW
    Drug Metab Dispos; 2011 Sep; 39(9):1650-7. PubMed ID: 21666065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism of UDP-glucuronosyltransferase (UGT2B15) and glucuronidation of paracetamol in healthy population.
    Mehboob H; Iqbal T; Jamil A; Khaliq T
    Pak J Pharm Sci; 2016 May; 29(3 Suppl):1037-41. PubMed ID: 27383482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
    Hsieh MC; Lin KD; Tien KJ; Tu ST; Hsiao JY; Chang SJ; Lin SR; Shing SJ; Chen HC
    Metabolism; 2010 Aug; 59(8):1139-44. PubMed ID: 20045142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.
    Nishihara M; Sudo M; Kamiguchi H; Kawaguchi N; Maeshiba Y; Kiyota Y; Takahashi J; Tagawa Y; Kondo T; Asahi S
    Drug Metab Pharmacokinet; 2012; 27(2):223-31. PubMed ID: 22123126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.
    Xu HR; Zhang JW; Chen WL; Ning ZQ; Li XN
    Clin Drug Investig; 2019 Jun; 39(6):553-563. PubMed ID: 31037611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of the microRNA response elements in the 3'-untranslated region of the UDP glucuronosyltransferase (UGT) 2B7 and 2B15 genes by a functional genomics approach.
    Papageorgiou I; Court MH
    Biochem Pharmacol; 2017 Dec; 146():199-213. PubMed ID: 28962835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
    Court MH; Hao Q; Krishnaswamy S; Bekaii-Saab T; Al-Rohaimi A; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2004 Aug; 310(2):656-65. PubMed ID: 15044558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.
    Court MH
    Drug Metab Rev; 2010 Feb; 42(1):209-24. PubMed ID: 19821798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of uridine diphosphate-glucuronosyltransferase 2B15 expression during ovulation in the rat.
    Dam PTM; Jang YJ; Park JI; Choi BC; Song SJ; Chun SY
    Endocr J; 2017 Jun; 64(6):605-612. PubMed ID: 28442641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.
    Chung JY; Cho JY; Yu KS; Kim JR; Lim KS; Sohn DR; Shin SG; Jang IJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):595-600. PubMed ID: 17687269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chiglitazar: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):87-92. PubMed ID: 34846697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human hepatic UGT2B15 developmental expression.
    Divakaran K; Hines RN; McCarver DG
    Toxicol Sci; 2014 Sep; 141(1):292-9. PubMed ID: 24980262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.